[Form 4] Standard BioTools Inc. Insider Trading Activity
Casdin-affiliated investment entities reported new open-market purchases of Standard BioTools Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Casdin-affiliated investment entities reported new open-market purchases of Standard BioTools Inc. common stock. Casdin Partners Master Fund, L.P., which is treated as a director and 10% owner, bought 250,000 shares on September 3, 2025 at a weighted average price of $1.2656 and another 250,000 shares on September 4, 2025 at a weighted average price of $1.2774.
After these transactions, the Master Fund indirectly beneficially owned 60,775,000 shares of Standard BioTools common stock. Footnotes state these securities are held directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin. Separate positions are also reported as held directly by Eli Casdin and by other Casdin private growth equity funds.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, $0.001 par value per share | 250,000 | $1.2774 | $319K |
| Purchase | Common Stock, $0.001 par value per share | 250,000 | $1.2656 | $316K |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
Footnotes (6)
- F1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2414 to $1.2765. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- F2. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
- F3. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2621 to $1.2930. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- F4. The securities are owned directly by Eli Casdin.
- F5. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
- F6. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
AI-generated analysis. How Rhea-AI works. Not financial advice.